Hologicvs.Labcorp
HOLX vs LH · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Labcorp is about 1.5× larger than Hologic by market cap; Labcorp trades at the lower P/E (25.3 vs 31.2); year to date, Labcorp leads (+25.2% vs +2.0%).
Side by side
| HOLX | LH | |
|---|---|---|
| Market cap | $17B | $25.3B |
| Price | — | $312.15 |
| Today | — | −0.7% |
| Return YTD | +2.0% | +25.2% |
| Return 1Y | −3.5% | +13.2% |
| P/E | 31.2 | 25.3 |
| P/S | 4.1 | 1.8 |
| P/B | 3.2 | 2.9 |
Data as of 2026-10-09 · updates daily after U.S. close
The two companies
HologicHOLX
Women's health defines the range here, from molecular diagnostic tests to mammography systems and surgical products.
Full HOLX profile →LabcorpLH
Samples from across the US end up in Labcorp's laboratories, which handle routine clinical testing alongside genomics and specialty assays. A contract research arm works for drug developers.
Full LH profile →More HOLX & LH comparisons
Other head-to-heads in the Diagnostics segment.
See where HOLX and LH sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →